Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2011 (2011), Article ID 985780, 9 pages
http://dx.doi.org/10.4061/2011/985780
Review Article

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer

1Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Received 30 June 2011; Accepted 16 July 2011

Academic Editor: Maria João M. Bugalho

Copyright © 2011 Maria E. Cabanillas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts and Figures, American Cancer Society, 2010.
  2. K. C. Bible, V. J. Suman, J. R. Molina et al., “Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study,” The Lancet Oncology, vol. 11, no. 10, pp. 962–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. L. L. Carr, D. A. Mankoff, B. H. Goulart et al., “Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation,” Clinical Cancer Research, vol. 16, no. 21, pp. 5260–5268, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., “Phase II trial of sorafenib in metastatic thyroid cancer,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1675–1684, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. A. Wells, B. G. Robinson, R. F. Gagel et al., “Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA),” Journal of Clinical Oncology, vol. 28, supplement, 2010. View at Google Scholar
  6. E. T. Lam, M. D. Ringel, R. T. Kloos et al., “Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2323–2330, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. A. De Souza, N. Busaidy, A. Zimrin et al., “Phase II trial of sunitinib in medullary thyroid cancer (MTC),” Journal of Clinical Oncology, vol. 28, supplement, 2010. View at Google Scholar
  8. Package insert sorafenib (Nexavar). In: Bayer HealthCare and Onyx Pharmaceuticals.
  9. Package insert vandetanib (Vandetanib). In: AstraZeneca Pharmaceuticals.
  10. R. J. Johnson, S. D. Kivlighn, Y. G. Kim, S. Suga, and A. B. Fogo, “Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease,” American Journal of Kidney Diseases, vol. 33, no. 2, pp. 225–234, 1999. View at Google Scholar · View at Scopus
  11. D. C. Sane, L. Anton, and K. B. Brosnihan, “Angiogenic growth factors and hypertension,” Angiogenesis, vol. 7, no. 3, pp. 193–201, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Schmidinger, D. Arnold, C. Szczylik, J. Wagstaff, and A. Ravaud, “Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice,” Cancer Investigation, vol. 28, no. 8, pp. 856–864, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. L. Veronese, A. Mosenkis, K. T. Flaherty et al., “Mechanisms of hypertension associated with BAY 43-9006,” Journal of Clinical Oncology, vol. 24, no. 9, pp. 1363–1369, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. A. J. Struijker Boudier, J. L. M. L. Le Noble, M. W. J. Messing, M. S. P. Huijberts, F. A. C. Le Noble, and H. Van Essen, “The microcirculation and hypertension,” Journal of Hypertension, vol. 10, no. 7, supplement, pp. S147–S156, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. B. I. Rini, D. P. Cohen, D. R. Lu et al., “Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib,” Journal of the National Cancer Institute, vol. 103, no. 9, pp. 763–773, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. M. L. Maitland, G. L. Bakris, H. R. Black et al., “Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors,” Journal of the National Cancer Institute, vol. 102, no. 9, pp. 596–604, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. Mallick, R. Kanthety, and M. Rahman, “Home blood pressure monitoring in clinical practice: a review,” American Journal of Medicine, vol. 122, no. 9, pp. 803–810, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Package insert sunitinib (Sutent). In: Pfizer Labs.
  19. Package insert pazopanib (Votrient). In: GlaxoSmithKline.
  20. A. Y. Khakoo, C. M. Kassiotis, N. Tannir et al., “Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor,” Cancer, vol. 112, no. 11, pp. 2500–2508, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. T. F. Chu, M. A. Rupnick, R. Kerkela et al., “Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib,” The Lancet, vol. 370, no. 9604, pp. 2011–2019, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. V. Chintalgattu, D. Ai, R. R. Langley et al., “Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress,” Journal of Clinical Investigation, vol. 120, no. 2, pp. 472–484, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, “Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186–193, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. T. V. Patel, J. A. Morgan, G. D. Demetri et al., “A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 282–284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. C. Frangié, C. Lefaucheur, J. Medioni, C. Jacquot, G. S. Hill, and D. Nochy, “Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma,” The Lancet Oncology, vol. 8, no. 2, pp. 177–178, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. K. Winn, S. Ellis, P. Savage, S. Sampson, and J. E. Marsh, “Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 673–675, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. V. Eremina, M. Sood, J. Haigh et al., “Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 707–716, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. N. Sternberg, I. D. Davis, J. Mardiak et al., “Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 1061–1068, 2010. View at Publisher · View at Google Scholar · View at PubMed
  29. B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib in advanced clear-cell renal-cell carcinoma,” New England Journal of Medicine, vol. 356, no. 2, pp. 125–134, 2007. View at Publisher · View at Google Scholar · View at PubMed
  30. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 22, pp. 3584–3590, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. F. A. B. Schutz, T. K. Choueiri, and C. N. Sternberg, “Pazopanib: clinical development of a potent anti-angiogenic drug,” Critical Reviews in Oncology/Hematology, vol. 77, no. 3, pp. 163–171, 2011. View at Publisher · View at Google Scholar · View at PubMed
  32. C. Robert, J. P. Arnault, and C. Mateus, “RAF inhibition and induction of cutaneous squamous cell carcinoma,” Current Opinion in Oncology, vol. 23, no. 2, pp. 177–182, 2011. View at Publisher · View at Google Scholar · View at PubMed
  33. M. E. Lacouture, A. Desai, K. Soltani et al., “Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor,” Clinical and Experimental Dermatology, vol. 31, no. 6, pp. 783–785, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. D. S. Hong, S. B. Reddy, V. G. Prieto et al., “Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib,” Archives of Dermatology, vol. 144, no. 6, pp. 779–782, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. J. P. Arnault, J. Wechsler, B. Escudier et al., “Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib,” Journal of Clinical Oncology, vol. 27, no. 23, pp. e59–e61, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. T. Kamba and D. M. McDonald, “Mechanisms of adverse effects of anti-VEGF therapy for cancer,” British Journal of Cancer, vol. 96, no. 12, pp. 1788–1795, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. C. F. Xu, B. H. Reck, Z. Xue et al., “Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism,” British Journal of Cancer, vol. 102, no. 9, pp. 1371–1377, 2010. View at Publisher · View at Google Scholar · View at PubMed
  38. H. Minami, K. Kawada, H. Ebi et al., “Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors,” Cancer Science, vol. 99, no. 7, pp. 1492–1498, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. J. L. Spivak, “Polycythemia vera: myths, mechanisms, and management,” Blood, vol. 100, no. 13, pp. 4272–4290, 2002. View at Publisher · View at Google Scholar · View at PubMed
  40. B. Y. Y. Tam, K. Wei, J. S. Rudge et al., “VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis,” Nature Medicine, vol. 12, no. 7, pp. 793–800, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. E. Wong, L. S. Rosen, M. Mulay et al., “Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity,” Thyroid, vol. 17, no. 4, pp. 351–355, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. M. E. Cabanillas, S. G. Waguespack, Y. Bronstein et al., “Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2588–2595, 2010. View at Publisher · View at Google Scholar · View at PubMed
  43. E. R. Plimack, N. Tannir, E. Lin, B. N. Bekele, and E. Jonasch, “Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon,” Cancer, vol. 115, no. 9, pp. 1859–1866, 2009. View at Publisher · View at Google Scholar · View at PubMed
  44. K. Kim, K. Flaherty, P. Champman et al., “Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM),” Journal of Clinical Oncology, vol. 29, supplement, 2011. View at Google Scholar
  45. J. A. Gottlieb and C. S. Hill Jr., “Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients,” New England Journal of Medicine, vol. 290, no. 4, pp. 193–197, 1974. View at Google Scholar
  46. K. Zimmermann, A. Schmittel, U. Steiner et al., “Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib,” Oncology, vol. 76, no. 5, pp. 350–354, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. A. Fernández, A. Sanguino, Z. Peng et al., “An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic,” Journal of Clinical Investigation, vol. 117, no. 12, pp. 4044–4054, 2007. View at Publisher · View at Google Scholar · View at PubMed